Cyberknife Treatment for Low and Intermediate Risk Prostate Cancer
Authors:
- B. DettiBDB. Detti
- P. BonomoPBP. Bonomo
- L. MasiLML. Masi
- R. DoroRDR. Doro
- S. CipressiSCS. Cipressi
- C. IermanoCIC. Iermano
- I. BonucciIBI. Bonucci
- D. FranceschiniDFD. Franceschini
- V. Di CataldoVCV. Di Cataldo
- L. Di BrinaLBL. Di Brina
- M. BakiMBM. Baki
- G. SimontacchiGSG. Simontacchi
- 1 April 2015
- journal article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 33 (5) , 188-192
Abstract
Cyberknife is an emerging treatment for early stage prostate cancer. Between October 2012 and January 2014, 32 patients were treated in our institution. Prescribed dose was 35-36.25 Gy in five fractions. Biochemical response was observed in 22 patients. Four patients experienced G2 acute genitourinary toxicity and in two cases we recorded G3 acute GU toxicity. 5 patients experienced G2 acute proctitis. At last follow up visit, all patients were still alive. 29 remained free of disease at last follow up appointment, while three developed a biochemical recurrence. Our experience confirms the efficacy and safety of Cyberknife for localized prostate cancer.Keywords
This publication has 18 references indexed in Scilit:
- Hypofractionated External Beam Radiotherapy to Boost the Prostate with ≥85 Gy/Equivalent Dose for Patients with Localised Disease at High Risk of Lymph Node Involvement: Feasibility, Tolerance and OutcomeClinical Oncology, 2014
- Treatment outcome of localized prostate cancer by 70 Gy hypofractionated intensity-modulated radiotherapy with a customized rectal balloonRadiation Oncology Journal, 2014
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Confirmation of a Low α/β Ratio for Prostate Cancer Treated by External Beam Radiation Therapy Alone Using a Post-Treatment Repeated-Measures Model for PSA DynamicsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncology Group/American College of Radiology 95-09Journal of Clinical Oncology, 2010
- Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trialThe Lancet Oncology, 2007
- Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 GyJournal of Clinical Oncology, 2006
- The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: Feasibility and acute toxicityInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- How low is the α/β ratio for prostate cancer?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2003
- Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissueInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002